- Home
- LTRY vs NTBL Comparison
LTRY vs NTBL Comparison
Compare LTRY & NTBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LTRY
- NTBL
- Stock Information
- Founded
- LTRY 2015
- NTBL 2000
- Country
- LTRY United States
- NTBL United States
- Employees
- LTRY N/A
- NTBL N/A
- Industry
- LTRY Computer Software: Prepackaged Software
- NTBL Biotechnology: Pharmaceutical Preparations
- Sector
- LTRY Technology
- NTBL Health Care
- Exchange
- LTRY Nasdaq
- NTBL Nasdaq
- Market Cap
- LTRY N/A
- NTBL 4.6M
- IPO Year
- LTRY N/A
- NTBL N/A
- Fundamental
- Price
- LTRY $0.49
- NTBL $0.25
- Analyst Decision
- LTRY
- NTBL Buy
- Analyst Count
- LTRY 0
- NTBL 2
- Target Price
- LTRY N/A
- NTBL $5.00
- AVG Volume (30 Days)
- LTRY 52.0K
- NTBL 8.1M
- Earning Date
- LTRY 11-29-2024
- NTBL 11-12-2024
- Dividend Yield
- LTRY N/A
- NTBL N/A
- EPS Growth
- LTRY N/A
- NTBL N/A
- EPS
- LTRY N/A
- NTBL N/A
- Revenue
- LTRY $5,723,382.00
- NTBL $313,000.00
- Revenue This Year
- LTRY N/A
- NTBL N/A
- Revenue Next Year
- LTRY N/A
- NTBL N/A
- P/E Ratio
- LTRY N/A
- NTBL N/A
- Revenue Growth
- LTRY 125.44
- NTBL 3812.50
- 52 Week Low
- LTRY $0.50
- NTBL $0.22
- 52 Week High
- LTRY $7.01
- NTBL $4.24
- Technical
- Relative Strength Index (RSI)
- LTRY 34.24
- NTBL 35.14
- Support Level
- LTRY $0.51
- NTBL $0.28
- Resistance Level
- LTRY $0.57
- NTBL $0.37
- Average True Range (ATR)
- LTRY 0.03
- NTBL 0.06
- MACD
- LTRY 0.01
- NTBL -0.01
- Stochastic Oscillator
- LTRY 0.00
- NTBL 6.26
About NTBL Notable Labs Ltd.
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.